Arcellx - רווח למניה בשנים עשר החודשים האחרונים ACLX

Positive trial results for CAR-T therapy in myeloma are creating current momentum, yet Arcellx operational processes rely on external CRO and CMO contractors. The fundamental EPS TTM metric visualizes capital accumulation phases, where -4.05 shows the value of this parameter. This underscores the status of an innovator creating safe cell engineering to save patients in critical conditions.

EPS TTM is calculated as the ratio of total annual net income to the number of shares outstanding, allowing for an assessment of the business's real profitability without market noise. By analyzing the EPS TTM dynamics of Arcellx (ACLX), an investor can see how R&D efficiency and the logistical stability of CAR-T therapy manufacturing partners convert into actual financial results per share of capital.